ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1195

NLP-Based Clustering Methods Can Efficiently Categorize Scientific Abstracts for Medical Conferences
Abstract Number: 1578

NLRP3 Inflammasome Pathway Expression at Atheroma Plaques from Peripheral Artery Disease According to the Uricemic Status
Abstract Number: 1362

No Change in Bone Marrow Edema of the Sacroiliac Joints and Spine After High Intensity Interval Training in PsA
Abstract Number: 0939

Non-steroidal Anti-inflammatory Drug Use Is Associated with Disease Activity and Reduced Significantly in Patients with Axial Spondyloarthritis Treated with Tumor Necrosis Factor Inhibitors; Data from a Real Life Experience
Abstract Number: 0543

Novel Insights into Systemic Sclerosis Using a Sensitive Computational Method to Analyze Whole-genome Bisulfite Sequencing Data
Abstract Number: 0124

Nurse-supported Web-based Cognitive Behavioral Therapy for Chronic Musculoskeletal Pain: An Effectiveness Trial
Abstract Number: 1320

Obesity and Its Associations with Clinical Manifestations and Disease Burden of Patients with Spondyloarthritis: An Ancillary Study from the ASAS-perSpA Project
Abstract Number: 0583

Obesity and Lower Socioeconomic Position Are Independently Associated with Incident Osteoarthritis and Rheumatoid Arthritis: Results from the English Longitudinal Study of Ageing
Abstract Number: 1942

Occurrence of Basal Cell and Squamous Cell Carcinomas of the Skin Under Different DMARD Therapies
Abstract Number: 0436

Ocular and Orbital Manifestations of Granulomatosis with Polyangiitis: A Systematic Review of Published Cases
Abstract Number: 0426

Ocular Manifestations of ANCA-Associated Vasculitis
Abstract Number: 1117

Ocular Scleral Pathology: Clinical Features and Systemic Treatment in 175 Patients from a Single University Center
Abstract Number: 1044

Older Patients with Rheumatic Disease Are Commonly Prescribed Potentially Inappropriate Medications
Abstract Number: 0080

One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
Abstract Number: 1284

One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].